Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.6 DKK | +1.60% | -1.10% | +50.79% |
May. 30 | Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review | CI |
May. 03 | Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024 |
- Stock Market
- Equities
- ALK B Stock
- News ALK-Abelló A/S
- Analyst Reco.